Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's first drug candidates are being developed for the treatment of two critical medical needs: the prevention and treatment of Acute Kidney Injury (AKI) with THR-184 and the treatment of fibrosis due to diabetic nephropathy in Chronic Kidney Disease (CKD) with THR-123.

THR-184, a peptide formulated for intravenous delivery, has demonstrated excellent control of biomarker and functional changes in an extensive series of preclinical models of AKI. The peptide controls inflammation and prevents apoptosis of renal tubule cells, resulting in protection and repair of the kidney following injury. All preclinical toxicology testing has been completed and THR-184 is now in Phase 1 clinical testing for safety and pharmacokinetic evaluation. Phase 2 efficacy testing is planned for 2012.

THR-123 is an orally active peptide that has shown significant control of fibrosis in preclinical models of CKD. This drug candidate is being developed to treat moderate and severe CKD. THR-123 has the potential to work as a stand-alone therapy or in combination with conventional angiotensin converting enzyme (ACE) inhibitors. The full pharmacokinetic and pharmacodynamic profiles are being completed and THR-123 is on track to progress to clinical testing by 2013.